200 related articles for article (PubMed ID: 16151910)
1. Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase alfa.
Wendt S; Whybra C; Kampmann C; Teichmann E; Beck M
J Inherit Metab Dis; 2005; 28(5):787-8. PubMed ID: 16151910
[TBL] [Abstract][Full Text] [Related]
2. Treatment with agalsidase beta during pregnancy in Fabry disease.
Politei JM
J Obstet Gynaecol Res; 2010 Apr; 36(2):428-9. PubMed ID: 20492401
[TBL] [Abstract][Full Text] [Related]
3. Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease.
Senocak Tasci E; Bicik Z
Iran J Kidney Dis; 2015 Sep; 9(5):406-8. PubMed ID: 26338166
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of enzyme replacement therapy in Fabry disease.
Barbey F; Hayoz D; Widmer U; Burnier M
Curr Med Chem Cardiovasc Hematol Agents; 2004 Oct; 2(4):277-86. PubMed ID: 15320778
[TBL] [Abstract][Full Text] [Related]
5. Uneventful pregnancy outcome after enzyme replacement therapy with agalsidase beta in a heterozygous female with Fabry disease: A case report.
Germain DP; Bruneval P; Tran TC; Balouet P; Richalet B; Benistan K
Eur J Med Genet; 2010; 53(2):111-2. PubMed ID: 20045092
[TBL] [Abstract][Full Text] [Related]
6. Agalsidase alfa: specific treatment for Fabry disease.
Mehta A
Hosp Med; 2002 Jun; 63(6):347-50. PubMed ID: 12096664
[TBL] [Abstract][Full Text] [Related]
7. Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.
Feriozzi S; Linhart A; Ramaswami U; Kalampoki V; Gurevich A; Hughes D;
Clin Ther; 2020 Dec; 42(12):2321-2330.e0. PubMed ID: 33218740
[TBL] [Abstract][Full Text] [Related]
8. Renal complications of Fabry disease.
Basic-Jukic N; Kes P; Coric M; Basic-Kes V
Curr Pharm Des; 2013; 19(33):6046-50. PubMed ID: 23448456
[TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease.
Kalkum G; Macchiella D; Reinke J; Kölbl H; Beck M
Eur J Obstet Gynecol Reprod Biol; 2009 May; 144(1):92-3. PubMed ID: 19233535
[No Abstract] [Full Text] [Related]
10. Update on role of agalsidase alfa in management of Fabry disease.
Ramaswami U
Drug Des Devel Ther; 2011 Mar; 5():155-73. PubMed ID: 21552486
[TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
Wang RY; Abe JT; Cohen AH; Wilcox WR
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
[TBL] [Abstract][Full Text] [Related]
12. Fabry disease: overall effects of agalsidase alfa treatment.
Beck M; Ricci R; Widmer U; Dehout F; de Lorenzo AG; Kampmann C; Linhart A; Sunder-Plassmann G; Houge G; Ramaswami U; Gal A; Mehta A
Eur J Clin Invest; 2004 Dec; 34(12):838-44. PubMed ID: 15606727
[TBL] [Abstract][Full Text] [Related]
13. Agalsidase alfa: a review of its use in the management of Fabry disease.
Keating GM
BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
[TBL] [Abstract][Full Text] [Related]
14. Enzyme replacement therapy of Fabry disease.
Clarke JT; Iwanochko RM
Mol Neurobiol; 2005 Aug; 32(1):43-50. PubMed ID: 16077182
[TBL] [Abstract][Full Text] [Related]
15. Histologic abnormalities of placental tissues in Fabry disease: a case report and review of the literature.
Thurberg BL; Politei JM
Hum Pathol; 2012 Apr; 43(4):610-4. PubMed ID: 22078290
[TBL] [Abstract][Full Text] [Related]
16. Fabry disease: a treatable lysosomal storage disorder.
Phadke SR; Mandal K; Girisha KM
Natl Med J India; 2009; 22(1):20-2. PubMed ID: 19761154
[TBL] [Abstract][Full Text] [Related]
17. Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety.
Beck M
Expert Opin Biol Ther; 2009 Feb; 9(2):255-61. PubMed ID: 19236256
[TBL] [Abstract][Full Text] [Related]
18. The utility of the FIPI score in predicting long-term clinical outcomes in patients with Fabry disease receiving enzyme replacement therapy with agalsidase alfa.
Mac Lochlainn DJ; McKechnie DGJ; Mehta AB; Hughes DA
Mol Genet Metab; 2018 Feb; 123(2):154-158. PubMed ID: 29055531
[TBL] [Abstract][Full Text] [Related]
19. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey.
Hoffmann B; Beck M; Sunder-Plassmann G; Borsini W; Ricci R; Mehta A;
Clin J Pain; 2007; 23(6):535-42. PubMed ID: 17575495
[TBL] [Abstract][Full Text] [Related]
20. [Results of enzyme replacement therapy in Fabry disease nephropathy].
Dussol B
Presse Med; 2007 Mar; 36 Spec No 1():1S43-7. PubMed ID: 17546767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
